author-photo

Ksenia Titorenko

Novartis

6

Papers

53

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (22)
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

2019 Blood
Show All
- Source
- Cite
- Save
Citations (19)